A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis

We evaluated the efficacy, pharmacokinetics, and safety of adalimumab in Japanese patients with active ankylosing spondylitis (AS) who had an inadequate response to, or who were intolerant of, treatment with ≥1 nonsteroidal anti-inflammatory drugs (NSAIDs). This phase 3, multicenter, open-label tria...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kobayashi, Shigeto, Harigai, Masayoshi, Mozaffarian, Neelufar, Pangan, Aileen L., Sharma, Shringi, Brown, L. Steven, Miyasaka, Nobuyuki
Format: Artigo
Langue:Inglês
Publié: Springer Japan 2011
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3416976/
https://ncbi.nlm.nih.gov/pubmed/22205117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10165-011-0557-x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires